The substantial cost reductions and influx of cash improve Lexicon's financial runway, reducing near-term dilution risk. Positive regulatory feedback on pilavapadin and progress in pivotal trials for sotagliflozin represent key upcoming catalysts. Traders should monitor enrollment progress in the SONATA-HCM trial and timing of the NDA resubmission for T1D.
Price Chart
Executive Summary
Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5 million in revenue, driven by licensing income from Novo Nordisk and INPEFA sales. The company reduced R&D and SG&A expenses significantly year-over-year, cutting its net loss by over half. It also strengthened its balance sheet with $106.7 million in new cash from a stock sale and a milestone payment. Key pipeline progress includes advancing sotagliflozin for HCM and T1D, and preparing pilavapadin for Phase 3 trials in neuropathic pain.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $5.5 million, down from $26.6 million in Q4 2024 (primarily due to a $25M upfront payment from Viatris in 2024)
- Net loss narrowed to $15.5 million in Q4 2025 from $33.8 million in Q4 2024
- Full-year 2025 net loss was $50.3 million, a 75% improvement from $200.4 million in 2024
- Received $106.7 million in new cash in February 2026 ($96.7M from stock sale, $10M milestone from Novo Nordisk)
- Cash, investments, and restricted cash totaled $125.2 million as of December 31, 2025
- R&D expenses decreased to $11.3 million in Q4 2025 from $26.7 million in Q4 2024
- SG&A expenses decreased to $8.8 million in Q4 2025 from $32.3 million in Q4 2024
- SONATA-HCM Phase 3 trial is over 50% enrolled, with completion expected mid-2026
- Positive End-of-Phase 2 meeting with FDA for pilavapadin supports advancement to Phase 3
- NDA resubmission for sotagliflozin in T1D targeted for 2026
Financial Impact
Reduced annual net loss by $150.1 million year-over-year and added $106.7 million in new cash, significantly extending runway for clinical development
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| INPEFA | $1.1M | -31.9% |
Risk Factors
- Revenue decline reflects absence of large upfront payments; sustainable commercial growth from INPEFA remains limited ($1.1M in Q4)
- Future milestones and regulatory approvals are not guaranteed, particularly for sotagliflozin in T1D and pilavapadin in Phase 3
- High reliance on partnership funding (Novo Nordisk) for LX9851 development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062822-26-000047 |
| Document: lxrx-20260305.htm | 0001062822-26-000047 |
| Document: 0001062822-26-000047-index-headers.html | 0001062822-26-000047 |
| Document: 0001062822-26-000047-index.html | 0001062822-26-000047 |
| Document: 0001062822-26-000047.txt | 0001062822-26-000047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Aug 6, 2026 8w ago | Press Release | $2.36 $2.26 | ▼ −4.24% | ▼ −4.84% | $1.82 (−22.88%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.92 $2.22 | ▼ −15.63% | ▼ −13.85% | $1.82 (+5.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.89 $2.25 | ▲ +19.05% | ▲ +17.16% | $1.82 (−3.70%) |
May 6, 2026 21w ago | 8-K | $1.68 $1.85 | ▲ +10.12% | ▲ +6.98% | $1.82 (+8.33%) |
Apr 30, 2026 22w ago | 8-K | $1.63 $2.07 | ▼ −26.99% | ▼ −21.71% | $1.82 (−11.66%) |
Apr 30, 2026 22w ago | Press Release | $1.61 $2.21 | ▲ +37.27% | ▲ +32.30% | $1.82 (+13.04%) |
Mar 24, 2026 27w ago | Press Release | $1.72 $1.82 | ▲ +5.81% | ▼ −3.09% | $1.82 (+5.81%) |
Mar 23, 2026 27w ago | Press Release | $1.64 $1.83 | ▲ +11.59% | ▲ +4.17% | $1.82 (+10.98%) |
Mar 16, 2026 28w ago | DEFA14A | $1.62 $1.86 | ▲ +14.81% | ▲ +10.51% | $1.82 (+12.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access